



Emergent BioSolutions Files Universal Shelf Registration Statement

November 13, 2008

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 12, 2008--Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has filed with the U.S. Securities and Exchange Commission (SEC) a universal shelf registration statement which, when declared effective, will permit the company to issue up to an aggregate of \$100 million of common stock, preferred stock, debt securities and warrants. Under this customary type of shelf registration, once effective, the company will have the flexibility to issue registered securities, from time to time, in one or more separate offerings or other transactions with the size, price and terms to be determined at the time of issuance. The registration statement also relates to the registration of 1,180,638 shares of common stock that the selling stockholders identified in the registration statement may sell from time to time.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

When available, copies of the prospectus, and any prospectus supplement relating to a particular offering, may be obtained by contacting Emergent BioSolutions Inc., 2273 Research Boulevard, Rockville, Maryland 20850, Attn: Vice President, Investor Relations.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immune-related biologic products, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's clinical pipeline includes programs focused on anthrax, botulism, typhoid, tuberculosis, hepatitis B and chlamydia.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including future capital requirements, future capital resources, the condition of financial markets, the ability to raise additional funds by selling equity or debt securities, the ability to obtain additional funding from the U.S. government, and other factors identified in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2008 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CONTACT: Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

BurrowsR@ebsi.com

or

Media Contact:

Kimberly B. Root

Director, Public Affairs

517-327-1543

RootK@ebsi.com

SOURCE: Emergent BioSolutions Inc.